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The Relationship between Hot Flashes and Sleep Quality in Women Being Treated for Breast
Cancer
Carly Pabon
ABSTRACT
Hot flashes are one of the most bothersome symptoms experienced by women who have
undergone breast cancer treatment-induced menopause. This vasomotor symptom has been
hypothesized to be responsible for decreased sleep quality. This study further investigated the
relationship between hot flashes and sleep quality in this population.
The convenience sample consisted of 30 women being seen at an outpatient clinic in a
comprehensive cancer center in southwest Florida. All participants were between the ages of 3665, had a diagnosis of breast cancer and were currently taking a selective estrogen receptor
modulator for at least six weeks. The participants completed the Hot Flash Diary, Hot Flash
Questionnaire, Hot Flash Related Daily Interference Scale, Pittsburgh Sleep Quality Index and a
demographic form.
The mean sleep score of the sample was 9.33 (SD= 4.4). Global sleep scores above five
are indicative of poor sleep quality, and global sleep scores of eight or more have been linked to
cancer-related fatigue. Sleep was strongly correlated with hot flash distress (r = .754, p. = .000)
and hot flash severity (r = .718, p. = .000) and moderately correlated with hot flash interference
(r = .507, p. = .004) and hot flash frequency while asleep (r = .680, p. = .000).
The small sample size was a study limitation. However, study results do support findings
from previous studies. This study addresses a symptom management problem that may give
nurses better understanding of the experiences of their patients. These findings also may assist
iv

patients in helping their providers to understand the frustration they are experiencing with regard
to their decreased sleep quality.
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Chapter One
Introduction
Hot flashes are among the most common symptoms in women experiencing
menopause. After breast cancer treatment-induced menopause, about 65% of women will
have sudden episodes of intense warmth, which may begin in the chest and progress to
the neck and face. Hot flashes may be accompanied by other bothersome symptoms such
as anxiety, palpitations, profuse sweating, and red blotching of the skin (Finck, Barton,
Loprinzi, Quella &, Sloan, 1998; Shanafelt, Barton, Adjei &, Loprinzi, 2002).
The concept of a decrease in sleep quality (waking episodes) in postmenopausal
women with hot flashes has been accepted since 1981 (Erlik et al., 1981). However, it is
only in the past 10 years that this topic has been investigated further to benefit the women
experiencing this symptom distress. Women who are severely bothered by hot flashes
may be placed on estrogen therapy, which has been shown to be the most effective choice
to eliminate hot flashes in postmenopausal women (Carpenter et al., 1998; Jacobson et
al., 2001). However, women with breast cancer are not given this option; because
estrogen has been contraindicated for this population (Carpenter et al., 1998). Other
pharmaceuticals and alternative therapies used to treat hot flashes, such as black cohosh,
venlafaxine, clonidine, and gabapentin are currently under investigation (Carpenter et al.,
1998; Jacobson et al., 2001; Loprinzi et al., 2000; Shanafelt, Barton, Adjei &, Loprinzi,
2002).
1

Decreased sleep quality can be related to many different physiological responses,
and is often perceived by health care professionals as a symptom caused by anxiety or
depression, which are both common in the cancer population (Carpenter, Elam, Ridner,
Carney, Cherry & Cucullu, 2004). A review of the literature by Savard and Morin (2001)
concluded that between 30% and 50% of recently treated cancer patients reported sleep
problems. This problem has not been adequately addressed in breast cancer survivors
experiencing hot flashes.
Problem Statement
Women who go through menopause naturally are expected to have hot flashes and
sleep disturbances. It has been hypothesized that women who undergo breast cancer
treatment with tamoxifen (a selective estrogen receptor modulator or SERM) experience
decreased sleep quality and increased hot flash experience (including hot flash frequency,
severity, and distress) compared to their healthy counterparts (Carpenter & Andrykowski,
1999). In a study examining the circadian rhythm of postmenopausal breast cancer
survivors, hot flashes were experienced up to seven times a night. Twenty-one percent of
all hot flashes experienced by these women occurred between 11 p.m. and 6 a.m.
(Carpenter, Gautam, Freedman &, Andrykowski, 2001). This increase in hot flashes
during sleeping hours commonly disrupts the woman’s sleep. However, it is not presently
clear what characteristics of the hot flash experience are related to decreased sleep
quality.
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Research Purpose
The purpose of this study is to evaluate the relationships between the hot flash
experience and sleep quality in breast cancer patients who are taking a selective estrogen
receptor modulator.
Research Questions
The following research questions were addressed in this study.
For breast cancer survivors taking a selective estrogen receptor modulator, including
tamoxifen, toremifene and raloxifene:
1. Is there a relationship between hot flash frequency and sleep quality?
2. Is there a relationship between hot flash severity and sleep quality?
3. Is there a relationship between hot flash distress and sleep quality?
4. Is there a relationship between hot flash interference and sleep quality?
Definitions of Terms
The following terms are defined for the purposes of this study:
Hot Flash Experience: The full spectrum of a hot flash experience, including the
distress, frequency, interference, and severity perceived by the patient (Carpenter,
Johnson, Wagner, & Andrykowski 2002).
Hot Flash Frequency: Number of hot flashes in 24-hour period (Carpenter,
Johnson, Wagner, & Andrykowski, 2002).
Hot Flash Distress: The extent to which hot flashes are bothersome (Carpenter,
Johnson, Wagner, & Andrykowski, 2002).
Hot Flash Interference: The degree hot flashes interfere with daily living
(Carpenter, 2001).
3

Hot Flash Severity: The intensity of the hot flash physiological experience (Finck,
Barton, Loprinzi, Quella &, Sloan, 1998).
Sleep Quality: “Includes quantitative aspects of sleep, such as sleep duration,
sleep latency, or number of arousals, as well as more purely subjective aspects”(Buysse,
Reynolds, Monk, Berman &, Kupfer, 1989, p. 194).
Significance of the Problem
Women who experience SERM induced menopause endure a different hot flash
and sleep quality disturbance than those in natural menopause. The sleep pattern
disturbances of breast cancer survivors are currently clustered with anxiety and
depression without investigation into the impact of the woman’s hot flashes. This
inadequacy presents as missed assessments of the true etiology of the breast cancer
survivors’ poor sleep quality. Understanding the relationship between sleep quality and
hot flash severity, frequency, distress and sleep interference is necessary to provide
evidence based nursing care. However, current knowledge does not provide adequate
information for nurses to fully explore sleep quality in the breast cancer survivor in a
meaningful way. This research may add to the body of nursing knowledge from which
nursing assessments, teaching, interventions and research are derived.

4

Chapter Two
Review of Literature
It was first hypothesized in a study by Erlik et al. (1981) that hot flashes affected
sleep. Since that time there have been countless research studies on both hot flashes and
sleep. First, the conceptual framework will be discussed. This will be followed by a
review of literature that focuses on menopausal symptoms and hot flashes in breast
cancer patients. Then, literature is presented examining sleep in these patients and the
impact that it has on the quality of life of those being studied. Finally a synthesis of the
two topics, hot flashes and sleep in the breast cancer survivor is reviewed.
Model of Symptom Management
The framework for this study is the Model of Symptom Management created by
the University of California, San Francisco School of Nursing (Larson et al., 1994). This
framework focuses on the subjective view of the patient for gathering data and symptom
management. This model focuses on three interrelated components: Symptom
experience, symptom management strategies, and symptom outcomes.
This model exemplifies a comprehensive approach to symptom management,
focusing on the three components and the integration to form the best possible strategy
for care. The first dimension of the model of symptom management is the symptom
experience, which contains the patient’s perception of his or her symptoms, the
evaluation of those symptoms, and the patient’s response to those symptoms. In this case
5

the symptom experience would be that of the hot flash experience and of sleep
disturbance (Larson et al., 1994). This is the dimension of this framework that was the
focus of this study.
The second dimension is symptom management strategies. This is the symptom’s
treatment that has been found acceptable for the patient, the family and the healthcare
provider. These strategies may be aimed at one or more components of the symptom
experience. This is what can be perceived as the goal in most of the research discussed
here. The research is designed with the thought that better understanding of the first
dimension may help us to improve this second dimension.
The third and last dimension of the Symptom Management Model is symptom
outcomes. These have been conceptualized as 10 multidimensional indicators including:
symptom status, financial status, self care ability, quality of life, morbidity and comorbidity, mortality, health service utilization, functional status, and emotional status.
Symptom status is central and influences the other indicators, and hot flashes and sleep
heavily influence this dimension. That can be determined by examining this dimension.
Review of Empirical Literature
Hot Flashes and Breast Cancer
The purpose of the cross sectional descriptive study by McPhail and Smith (2000)
was to evaluate the menopausal symptom experience in both women who were receiving
adjuvant chemotherapy for treatment of breast cancer and women who were without
breast cancer. Four hundred questionnaires were sent out to participants in the two
groups, obtained from either a cancer center in Scotland where the women were receiving
adjuvant chemotherapy or a breast screening service where the women had no cancer
6

diagnosis. One hundred and thirty-nine breast cancer patients returned the questionnaires,
while 99 of the healthy women returned questionnaires. The instrument in the
questionnaire was newly developed for this study and consisted of three sections: general
health and menstrual history; questions about patient’s breast cancer diagnosis, cancer
treatment and symptoms (not included for the healthy women); and questions to assess
menopausal history and symptoms. Excluded from this study were those who had
recurrent or metastatic disease, those over 65 years of age, those with a history of a comorbid disease process, and those who were unable to complete the packet
independently.
The study (McPhail & Smith, 2000) revealed four symptoms significant to breast
cancer patients compared with their healthy counterparts: increased tiredness (higher in
those receiving chemotherapy p = 0.016); increased hot flashes (more frequent in those
taking tamoxifen p = 0.002); and an increase in night sweats (p = 0.04). Healthy
counterparts reported an increased frequency of headaches compared to the breast cancer
patients (p = 0.025). These investigators concluded that hot flashes were the second most
common symptom of breast cancer survivors and that this symptom was significantly
worse for breast cancer patients than for healthy women.
Carpenter and Andrykowski (1999) conducted telephone interviews of postmenopausal breast cancer survivors who were at least three months post-treatment (n =
114) to identify the most commonly reported menopausal symptoms. Menopausal status
and symptoms were assessed using questions adapted from the Massachusetts Women’s
Health Study and an adapted version of the Blatt Menopausal Index and Severity Index,
respectively. Quality of life was assessed using the SF-12 Health Survey. Seventy-five
7

percent or more of the sample reported joint pain, feeling tired, trouble sleeping, and hot
flashes/night sweats. Fifty-nine percent of those reporting hot flashes ranked them as
being quite a bit or extremely severe. Sleep disturbance was reported in 77% of the study
population, with 43% of these calling the severity quite a bit or extreme. A higher
prevalence and severity of these symptoms was correlated with lower physical (r = -0.36)
and emotional (r = -0.44) quality of life.
Carpenter et al. (1998) conducted a study of the prevalence and severity of hot
flashes and associated variables. The study also examined the knowledge of the breast
cancer survivors on hot flash treatment and the relationship between the hot flashes and
quality of life. The women were no longer receiving treatment for breast cancer, with the
exception of tamoxifen. Participants were sent a questionnaire packet to complete while
on the phone with study personnel. The packet included demographic questions, and
questions that were adapted from the Massachusetts Women’s Health Study regarding
menopausal status. Also included were instruments assessing current and past hot flash
management and a quality of life survey.
Hot flashes were reported in 65% of postmenopausal women with breast cancer
and 72% of women taking tamoxifen. These analyses showed that women more likely to
have severe hot flashes were typically greater in body mass index (p < 0.05), younger at
diagnosis (p < 0.01), had received chemotherapy (p < 0.05) and were users of tamoxifen
(p < 0.01). Women with hot flashes reported a lower quality of life (p < 0.10). Study
limitations included a small sample and one geographic area. Also, hot flash information
was limited to prevalence, severity and symptom bother. The data would be more
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informative if compared to a group of menopausal women without breast cancer, as well
as inclusion of daily frequency, daily pattern, and intensity (Carpenter et al., 1998).
A study conducted by Carpenter, Johnson, Wagner, and Andrykowski (2002)
compared the severity of hot flashes in breast cancer survivors with healthy women going
through menopause. Breast cancer survivors (n = 67) were age-matched (within 2 years)
to healthy menopausal subjects. The breast cancer group had a first time diagnosis of
breast cancer, no other cancer diagnosis, was disease free at the time of enrollment, three
months past any treatment (including chemotherapy, radiation therapy or surgery) with
the exception of tamoxifen (which they needed to be on for six weeks prior to the start of
the study), and less than or equal to six years after diagnosis. The healthy women had no
history of cancer, and an intact uterus and ovaries. A packet was sent to each woman
describing the study and containing several instruments: a demographic, disease and
treatment form, and gynecologic and reproductive history form for menopausal status;
questions from the Massachusetts Women’s Health Study to determine menopausal
status; Profile of Mood States Short Form; Positive and Negative Affect Scale; Hot
Flash-Related Daily Interference Scale; and a hot flash questionnaire. The hot flash
questionnaire items included severity, bother, quality, aggravating factors, alleviating
factors, and temporal pattern. A 48-hour detailed hot flash diary also was included for
completion. The 48-hour hot flash diary is considered the gold standard of subjective hot
flash frequency and severity measurement (Barton et al., 1998; Carpenter et al., 1998).
Results were that breast cancer survivors have more frequent (p = 0.006), more severe (p
= 0.001), more bothersome (p = 0.001) and longer (p = 0.002) hot flashes than their
healthy counterparts. Findings also suggest that if women continue to have hot flashes,
9

they are more prone to negative psychosocial effects (p < 0.005). Therefore, alleviating
hot flashes may improve overall quality of life, including mood, affect, sleep,
concentration, and sexuality.
Quality of life is a focus of cancer patient care. Stein, Jacobsen, Hann, Greenberg
and, Lyman, in 2000, focused on the impact of hot flashes on quality of life. This study
examined 70 postmenopausal women with breast cancer who were over 18, receiving
adjuvant chemotherapy or radiotherapy, without unstable medical problems or neurologic
disorders, and without history of other cancers. Using nine different measurements, the
impact of hot flashes on their quality of life was determined. All of the data was collected
4-6 weeks after the start of therapy. Of the 70 women in the study, 42 were receiving
radiation therapy, and 28 chemotherapy, 6 were also taking tamoxifen. The measures
used in the study included, a demographic data form, the SF-36 health survey, Memorial
Symptom Assessment Scale, State-Trait Anxiety Inventory, Center for Epidemiological
Studies Depression Scale, Profile of Mood States Fatigue Scale, Fatigue Symptom
Inventory, Multidimensional Fatigue Symptom Inventory, and the Pittsburgh Sleep
Quality Index.
Forty percent of the 70 women in the study by Stein et al. (2000) were having hot
flashes. Sixty-seven percent stated that they were moderate to severe, and 58% stated that
they were somewhat to very much distressed by the symptom. Compared to the women
in the study who did not report having hot flashes, the women with hot flashes were 66%
more fatigued, 63% had poorer sleep quality, and 20% had poorer health.
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Sleep and Cancer
Engstrom, Strohl, Rose, Lewandowski and, Stefanek (1999) conducted a study on
sleep disturbances in patients with cancer. A convenience sample of lung cancer (n=57)
and breast cancer (n=93) patients was studied. Inclusion criteria included that the patient
had to have received (67%) or be currently (33%) receiving either chemotherapy,
hormone therapy, radiation therapy, surgery, or was considered to be receiving supportive
care only. An 82-item detailed questionnaire was administered over the phone.
The results of the study found no relationship between sleep disturbances and day
naps, pain or nausea, diagnosis, stage of disease, or treatment. Forty-four percent reported
sleep disturbances occurring within one month of the assessment. Only 16.6% of those
patients reported sleep problems to a nurse or doctor. When asked why they did not
report sleep symptoms one patient stated, “I thought it was not as important as having the
cancer itself” (Engstrom et al., 1999, p. 149).
Fortner, Stepanski, Wang, Kasprowicz and Durrence (2002) conducted a cross
sectional survey of breast cancer and medical patients to investigate the characteristics of
their sleep. Seventy-two breast cancer patients and 50 healthy women were given the
Pittsburgh Sleep Quality Index and Rand 36 item Health Survey. Of the 72 breast cancer
patients, 19 were pre-cancer treatment, 29 were receiving treatment and 23 had received
treatment in the past. Sixty-one percent of the breast cancer patients had a significant
decrease in sleep quality. This was attributed to several things. The most frequent reason
for sleep disturbance was reported to be the need to use the bathroom, followed by
feeling too hot, middle of the night or early awakening, and coughing or sneezing loudly.
The only reported difference between the healthy group and breast cancer group was the
11

use of medication to facilitate sleep, with breast cancer patients more likely to use
medications than their healthy counterparts. There was also a decreased amount of total
sleep time of the breast cancer group compared to the healthy group.
Kravitz et al. (2003) created a large study depicting the differences in sleep in
midlife women when considering ethnicity and the different stages of menopause. There
were 12,603 participants in this study, all of whom were between 40 and 55 years of age.
Ethnicity was defined as either African American, Caucasian, Chinese, Japanese or
Hispanic. Menopausal status was defined as premenopausal, early perimenopausal, late
perimenopausal, naturally postmenopausal, surgically postmenopausal, or
postmenopausal on hormone replacement therapy. Subjects were all requested to take a
12-item symptom questionnaire regarding sleep and a demographic form, which helped
to determine stage of menopause. The women who were the least likely to have sleep
difficulties were premenopausal and Japanese. The women most likely to have sleep
difficulties were Caucasian, had higher education, vasomotor symptoms (hot flashes),
psychologic symptoms, increased perceived stress, poorer self perceived health,
decreased quality of life, decreased physical activity, current smokers and a diagnosis of
arthritis. Forty percent of Caucasian women, 38% of Hispanic women, 35% of African
American women, 31% of Chinese women, and 28% of Japanese women reported sleep
difficulty. Late perimenopausal women were the most common menopausal status group
to have sleep difficulty.
Hot flashes and Sleep in the Breast Cancer Survivor
It is important to understand the potential for sleep disruptions in women who are
breast cancer survivors because this is what will fuel the treatments of the future.
12

Carpenter, Gautam, Freedman and Andrykowski (2001) took on the investigation of the
circadian rhythm of objectively recorded hot flashes in this population. Twenty-one
women were connected to a sternal skin conductance monitor for 24 hours to record hot
flash activity. These women all had a first time diagnosis of breast cancer, were
postmenopausal, 3 months post diagnosis, were currently disease free, and currently
having hot flashes but not taking medication to treat them. The women, in addition to
being connected to a monitor for 24 hours, were asked to keep an activity diary keeping
track of activities, including exercise, work, driving, bed time and sleep time and
perceived hot flashes. The findings from this study suggest that the circadian rhythm is
disrupted among breast cancer survivors. Twenty-one percent of hot flashes were
between 11 p.m. and 6 a.m. and half the sample had at least three and up to seven hot
flashes during sleep. This significant number of hot flashes during sleep hours leads to
fatigue, poor sleep quality and sleep disturbances (Carpenter et al., 2004). The limitations
of this study were suggested to be a small sample size, only a 24 hour recording period
and lack of a control group.
Carpenter et al., (2004) compared hot flashes, sleep quality and disturbance,
fatigue and depressive symptoms between breast cancer survivors (n = 46) and healthy
women. Criteria for breast cancer was older than 21, English speaking, peri or
postmenopausal, experiencing daily hot flashes, in good general health, not depressed,
not taking hot flash treatment, first diagnosis of cancer, disease free at time of study
enrollment, at least 4 weeks post cancer treatment and, if applicable, on tamoxifen for at
least 6 weeks. These women were matched to healthy women. The subjects were given a
demographic form, the Pittsburgh Sleep Quality Index, the Profile of Mood States Short
13

Form, and Center for Epidemiological Studies-Depression Scale, and were monitored
with a sternal skin conductance monitor to assess hot flashes. The monitor was placed on
the subject for two 24-hour periods spaced one week apart. The women were also asked
to complete a hot flash diary to assist in interpreting the data from the monitor. The
results of the study were that both groups reported similar sleep quality, though breast
cancer survivors experienced more nighttime hot flashes than the healthy women did.
Both samples were found to have had a symptom cluster of poor sleep, fatigue and
depression, possibly related to menopausal status (Carpenter et al., 2004).
The last study in this review seems to connect the rest of the studies that were
reviewed. This study by Savard et al. (2004) assessed the relationship between
objectively measured nighttime hot flashes and objectively measured sleep quality.
Participants were breast cancer survivors (n = 24) with a diagnosis of insomnia as
dictated by the International Classification of Sleep Disorders and Diagnostic and
Statistical Manual of Mental Disorders IV (American Psychiatric Association, 1994). The
measures used in this study included an Insomnia Interview Schedule, a medication
record, and the Hot Flash item of the European Organization for Research and Treatment
of Cancer and the Breast Cancer Specific Quality of Life Questionnaire. A skin
conductance monitor objectively measured the hot flashes. Sleep was objectively
measured by polysomnography, including electroencephalograph (EEG),
electromyography (EMG), and electrooculograph (EOG) recordings. Several variables
were measured with these instruments, including: time in bed, total wake time, total sleep
time, percentage of time in each stage of sleep, percentage of time awake, number and
duration of brief arousals, number of awakenings, sleep efficiency, latency time in each
14

stage of sleep, and number of changes from a higher level of sleep to a lesser level of
sleep. Each woman was studied three nights in the sleep lab, with data from only the last
two nights included in the data analysis to avoid a threat to external validity.
The data collected revealed that hot flashes could be associated with sleep
disruption in breast cancer survivors. There was an increase in the frequency of the hot
flashes between 3 a.m. to 5 a.m. and 11 p.m. to 12 a.m. with an increase in wake time and
higher number of stage changes to lighter sleep 10 minutes before or after the hot flash
was experienced. A limitation to the study was that when a hot flash was detected there
was a 20-minute window where a new hot flash could not be identified (Savard et al.,
2004). The subject is more likely to be awake making them unlikely to wake up again.
This may account for the lack of difference between the number of awakenings between
hot flash time and non hot flash time. This should be considered a limitation of this study.
Summary
The studies reviewed have suggested that there is a relationship between hot
flashes and sleep quality. It is clear that there is a difference between women who are
survivors of breast cancer who take tamoxifen and those who have never had the disease
in their menopausal experience. No studies were found that have subjectively evaluated
the relationship between each aspect of the hot flash symptom experience and sleep
quality.
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Chapter Three
Methods
This chapter presents the study design and methods. The purpose of this study is
to evaluate the relationships between the hot flash experience and sleep quality in breast
cancer patients who are taking a selective estrogen receptor modulator. The relationship
between hot flashes and sleep quality was evaluated using quantitative research with a
non-experimental correlational design. It was anticipated that breast cancer survivors who
have increased hot flash severity, distress, frequency, and interference would have
decreased sleep quality.
Sample
The setting for this study was an outpatient breast clinic in a comprehensive
cancer center in Southwest Florida. Women eligible to participate in the study had to
meet the following criteria: 1) a diagnosis of breast cancer, 2) currently taking a SERM,
either tamoxifen, toreifene, or raloxifene for at least six weeks, 3) be over age 18, 4) able
to read, write, and understand English, and 5) able to provide informed consent.
Exclusion criteria included a diagnosis of any other type of cancer, and treatment of any
cancer including radiation therapy, chemotherapy or surgery in the past six months to
avoid their confounding effects. A convenience sample of 88 women who had been
diagnosed with breast cancer and were currently taking a SERM was sought. Using
variables at an interval level of data, a Pearson's r was planned to describe the
16

relationship between two variables. With alpha at .05, two-tailed, a population correlation
coefficient of .30 for a moderate effect size, and a power of .80, the sample size needed
for this study was 88.
Instruments
The researcher reviewed four self-report measures with the participants. One
measure was gathered from the medical record by the researcher.
Hot Flash Diary
The Hot Flash Diary (Appendix A) is a brief questionnaire that was used to assess
patient perceptions regarding hot flash frequency, hot flash distress and hot flash severity.
This included definitions (Appendix B) that assisted the woman to place each of her hot
flashes in one of the four severity categories ranging from mild to very severe (Sloan et
al., 2001). The number of hot flashes the woman has experienced in the past 24 hours and
during her sleep was assessed with this instrument as well. Women were also asked to
provide an overall rating of how bothered they are by their hot flashes using a 10-point
numeric scale 0 (not at all) to 10 (extremely). This type of diary has been used
previously and is considered the gold standard for assessing hot flash frequency and
severity subjectively (Barton et al., 1998; Sloan et al., 2001). This Diary has been used to
assess hot flashes at present as well as hot flashes over an extended period of time. In this
study the Hot Flash Diary was used as a four-question twenty-four hour recall. Validity
and reliability has been reported by Sloan et al., (2001) who states that the Hot Flash
Diary has concurrent and discriminant validity and reliability from the study of a placebo
controlled trial.
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Hot Flash Related Daily Interference Scale
The Hot Flash Related Daily Interference Scale (HFRDIS) developed by
Carpenter (2001) is a 10-item scale measuring the degree hot flashes interfere with nine
daily activities; the tenth item measures the degree hot flashes interfere with overall
quality of life (Appendix C). The HFRDIS was developed to include daily life activities
specific to the impact of hot flashes. Participants rate the degree to which hot flashes have
interfered with each item during the previous week using a 0 (do not interfere) to 10
(completely interfere) point scale. A total score is computed by summing these items.
Higher scores indicate higher interference due to hot flashes and thus, greater impact on
quality of life. Women without hot flashes are asked to simply mark 0 for each item.
Internal consistency reliability was estimated with a Cronbach alpha coefficient and
reported to be 0.96. Validity was supported through 1) correlations with other hot flash
variables, 2) correlations with measures of affect and mood, 3) significant differences
between women with hot flashes and those without, and 4) demonstrated sensitivity over
time (Carpenter, 2001).
Pittsburgh Sleep Quality Index (PSQI)
Sleep quality was assessed using the PSQI, which is a standardized measure of
sleep quality. The PSQI (Appendix D) consists of 19 items which are combined to
produce a global sleep quality score and 7 component scores: sleep quality, sleep latency,
sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications,
and daytime dysfunction. Each of the component scores range from 0 (no difficulty) to 3
points (severe difficulty). These scores are summed to make the global score, which
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ranges from 0-21 and reflects the number and severity of sleep problems. This score was
used to determine sleep quality. Global scores of 5 or greater indicate poor sleep quality
and high sleep disturbance. In addition to being indicative of poor sleep quality and high
sleep disturbance, global scores of eight or more have been linked to cancer-related
fatigue in survivors of breast cancer and other cancers (Carpenter & Andrykowski, 1998).
In a psychometric evaluation of the PSQI in 1998 by Carpenter and Andrykowski, the
Cronbach’s alpha coefficient was calculated as 0.80 for the global sleep score.
Demographic and disease treatment information
A demographic form (Appendix E) was used to assess demographic information,
including birth date, ethnicity, and education level. Information was also gathered
(Appendix F) from the medical record including date and stage at diagnosis, how long
since last cancer treatment, what kind of treatments have been received, and when current
anti-estrogen therapy started.
Procedures
This study involved several procedural steps. The first step was approval from
Moffitt Cancer Center Protocol Review and Monitoring Committee to conduct the study,
followed by approval from the University of South Florida Institutional Review Board.
Following approval, potential subjects were identified for inclusion criteria by clinic
nurses in the Moffitt Cancer Center ambulatory clinic patients. Once identified, potential
subjects were approached regarding study participation. An informed consent and HIPPA
form was given to all participants (Appendix G and H). These forms included the title of
the study, the principal investigator, general information about the study, the plan of
study, the benefits and the risks of participation, and a statement about confidentiality.
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The study was explained, and all questions will be answered. After agreeing to
participate, the woman then signed the consent form and a copy was given to the woman
for her records. Following signed consent to participate, the women completed the Hot
Flash Diary, Hot Flash Questionnaire, Hot Flash Related Daily Interference Scale,
Pittsburgh Sleep Quality Index and a demographic form. Completing these scales took
about 15 minutes.
Data Analysis
The data analysis involved two steps. The first step was an analysis of
demographic and treatment information using descriptive statistics. The forms were
composed of interval data and nominal data.
Step two involved answering the research questions:
In breast cancer survivors on a selective estrogen receptor modulator:
1. Is there a relationship between hot flash frequency and sleep quality?
2. Is there a relationship between hot flash severity and sleep quality?
3. Is there a relationship between hot flash distress and sleep quality?
4. Is there a relationship between hot flash interference and sleep quality?
The data in each question was analyzed using Pearson’s correlations with alpha
set at .05.
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Chapter Four
Results, Discussion and Conclusions
This chapter presents the findings of the study. Included in this chapter are the
study results, discussion of the results, conclusions, and suggestions for future research.
Results
Demographic Data
The sample consisted of 30 patients, all women with ages ranging from 36 to 65
years with a mean age of 54 (SD=8.2). Years of education ranged from 12 to 18 years
with a mean of 14.2 years. The majority of patients (n=28) were Caucasian. The stage of
disease reported most frequently was stage I. Stage 0 represents carcinoma in situ (Table
1).

Table 1. Frequency and Percent of Women by Ethnicity and Stage of Disease
Variable
Ethnicity
White
Hispanic

Frequency
28
2

Percent
93.9
6.7

Stage
0
3
10
I
15
50
II
6
20
III
2
6.7
IV
1
3.3
Unknown
3
10
________________________________________________
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All of the patients had a diagnosis of breast cancer, half of them with right sided
occurrence (n=15). All of the women were taking tamoxifen. Twelve patients reported
that they had chronic illnesses. Types of cancer treatment are reported in Table 2.

Table 2. Frequency and Percent of Women by Type of Cancer Treatment
Medical Variable
Chemotherapy
Yes
No

Frequency

Percent

15
15

50
50

Type of SERM
Tamoxifen

30

100

Breast Surgery
Lumpectomy
MRM
RM
Unknown

20
5
3
2

Hysterectomy
With oopherectomy
Without oopherectomy
No

0
3
27

66.7
16.7
10
6.7

0
10
90

Radiation Therapy
Yes
17
56.7
No
13
43.3
_________________________________________________
Sleep Quality
Sleep quality was determined by the PSQI. Using a formula, the global sleep
quality was determined. A global sleep score above 5 is indicative of poor sleep quality
and a score of 8 or more has been linked to cancer related fatigue in breast cancer
patients. There are also some patients who are taking a sleep medication three or more
times a week (16.7 %). The majority of women (n = 24) had global sleep scores greater
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than 5, and 14 women (46.7 %) had global sleep scores greater than 8. Scores ranged
from 2 to 18 on a scale of 0-21; the mean for all patients (n=30) was 9.33 (SD=4.4).
Hot Flash Frequency
The patients answered two different questions regarding frequency. The first was
how many hot flashes they had experienced in the previous 24 hours and the second was
how many of those were experienced while the patients were sleeping. There were ten
patients who experienced no hot flashes. A mean of 3.7 (SD=4.8) hot flashes were
experienced by the patients in the previous 24 hours, the maximum number of hot flashes
reported was 24 in a 24 hour period. A mean of 1.3 (SD= 1.6) of those occurring while
the patient was sleeping, the maximum reported while sleeping was 7. The number of hot
flashes experienced in 24 hours was found to have a weak positive relationship with sleep
quality, however the result was not statistically significant (r=.306, p= .10) (Table 3). The
frequency of hot flashes experienced while sleeping had a moderate, positive, statistically
significant relationship with global sleep score (r=.507, p=.004) (Table 3).

Table 3. Correlations Between Global Sleep Scores and Hot Flash Experiences
Global Sleep Score
Hot Flashes
r
p
Severity
.718
.000
Distress
.754
.000
24 hour Frequency
.306
.100
Sleep Frequency
.507
.004
Interference
.680
.000
_________________________________________________________
Hot Flash Severity
Severity of hot flashes was determined by multiplying the number of hot flashes
experienced by the patient at each severity level and the severity level that they
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experienced and dividing it by the number of total hot flashes experienced. The mean was
1.16 (SD 9.9). This was on a scale from zero to four; zero equating to no hot flashes and
four meaning all very severe hot flashes. The patients were given definitions to use to
classify their hot flash severity. No patients reported very severe hot flashes (Table 4). A
strong, positive, statistically significant relationship was found between hot flash severity
and global sleep score (r=.718, p=.000) (Table 3).

Table 4. Number and Frequency of Hot Flashes Experienced by the Severity Score
Severity
Frequency
Percent
None
10
33.3
Mild
14
46.7
Moderate
12
40
Severe
9
30
Very Severe
0
0
_________________________________________________
Hot Flash Distress
Distress was measured by a zero to ten scale, zero meaning no distress and ten
meaning extremely distressed. The mean score was 3.4 (SD=3.5). A strong, positive,
statistically significant relationship was found between hot flash distress and global sleep
score (r=.754, p=.000) (Table 3).
Hot Flash Interference
The hot flash interference score is a sum of ten questions. This number is on a
scale of zero to one hundred, with zero implying hot flashes have no interference in the
patient’s life, and one-hundred meaning the most possible interference in the patient’s
life. Scores ranged from 0 to 75 with a mean interference score of 19.9 (SD=24.36). Hot
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flash interference was found to have a strong, positive, statistically significant
relationship with global sleep score (r=.680, p=.000) (Table 3).
Discussion
After approval from the Moffitt Cancer Center Protocol Review and Monitoring
Committee and the University of South Florida Institutional Review Board, data was
collected during the months of August through October of 2005. Few patients who were
approached were unwilling to participate in this study.
Demographic Data
The sample consisted of a convenience sample of 30 breast cancer patients who
were approached in an ambulatory care setting to participate in the study. The age range
of patients participating in the study was 36 to 65 years of age with a mean of 54. This
number is not representative of typical breast cancer patients due to the exclusion criteria.
Women over the age of 65 were excluded from the study because previous studies have
shown a decreased number of hot flashes on a SERM as women age. There were an equal
numbers of women with right sided and left sided breast cancer. The sample was mostly
Caucasian and few Hispanics with no African-American subjects. This is not
representative of the United States breast cancer patient population; 24% of those with
breast cancer are African American and 18% are Hispanic (Ries, 2004).
Another significant limitation of this study was the lack of patients found to be on
a SERM. Rather, patients who are taking aromatase inhibitors (AI) as their anti-estrogen
therapy seemed to be much more common. This is partly due to studies that have recently
been published supporting AI therapy in both postmenopausal women and women with a
breast cancer recurrence. Although hot flashes have been proven to be a bothersome side
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effect for women who are taking a SERM, the AI had fewer incidences of hot flashes in
preliminary studies. However, there is newer literature stating hot flashes are just as
common in women who are taking an AI as those taking a SERM (Morales, 2004).
Future research should compare the two classes of drugs according to women’s sleep
quality.
Sleep Quality
The mean global sleep quality score for these patients was 9.33, which indicates
poor sleep quality. However, it is not only hot flashes that may influence sleep quality.
Cancer patients typically have sleep problems related to their cancer diagnosis and
disease process. Some patients in the sample were taking a sleep medication three or
more times a week (16.7 %). This could have improved their sleep quality regardless of
hot flashes. There are also many patients who are taking anti-depressant medications in
the selective serotonin receptor modulator class in which a common side effect from
these drugs is insomnia (Karch, 2006). Thus, there were confounding factors that might
have influenced sleep quality.
Hot Flash Frequency
The time of the day that the hot flashes were experienced played a very important
role when considering frequency. The frequency of hot flashes experienced during the
day had no significant relationship to sleep quality. Only the frequency of hot flashes at
night were influential on patients sleep quality. This finding supports earlier research by
Carpenter, Gautam, Freedman and Andrykowski (2001) which both used objective hot
flash data collection from skin conductance monitoring and a 24 hour diary. This data
also supports research done by Savard et al. (2004) which also used objective measures
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including hot flash skin conductance monitoring and objective sleep monitoring by
polysomnography, EEG, EMG and EOG readings.
Hot Flash Severity
The severity of hot flashes had a very significant relationship with global sleep
quality scores. There were no patients who reported having very severe hot flashes, yet it
appears that the severity was strong enough to impact sleep quality. Women do not have
to have severe hot flashes for them to be affecting their sleep. Limitations to this variable
would include that some patients needed further prompting to quantify a number of hot
flashes in each severity category.
Hot Flash Distress
Distress was quantified by one item. This one item had the strongest correlation
with sleep quality scores. It is, therefore, the biggest predictor of poor sleep quality.
Asking a woman how bothered she is by her hot flashes on a scale from 0 to 10 will
predict how she is sleeping. This is a vital piece of information to be gathered when
caring for her. A decreased sleep quality may then be addressed. Although the validity of
this item has not been published, this strong, significant relationship would tend to
support its validity.
Hot Flash Interference
The relationship between hot flash interference and global sleep score was strong
and positive. The influence that hot flashes have on all aspects of the woman life
correlates with the lack of sleep quality. Therefore, if women are having a difficult time
sleeping because of their hot flashes they are most likely having trouble with hot flashes
interfering with other life issues such as sexuality and enjoyment and quality of life. This
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instrument was previously shown to have good reliability and validity, and results of this
study further support its validity.
Conclusions
Hot flashes are a very common symptom for women who are taking a SERM. It
seems that it is not the number of hot flashes alone that is decreasing the sleep quality of
these women, but how distressing, severe and interfering the symptom is to them.
Although results do not demonstrate a cause and effect, they do suggest that relieving hot
flashes may have a positive effect on other aspects of quality of life including sleep.
Recommendations for future research
The prominence of aromatase inhibitors in the breast cancer population warrants
similar studies with those medications, even comparing them with SERMs. A larger
sample size, having a multi-site study in a broader geographical area and recruiting more
African American women would all be recommendations for future research.
Oncology nursing education should include content about the likelihood of hot
flashes and their impact not only on sleep quality, but on all aspects of everyday life.
Assessment of hot flashes is one of the most important things nurses can do to assist their
patients who are taking a SERM. Nurses should inquire about how bothersome the hot
flashes are and ask if the hot flashes are interfering with sleep. Recommending
techniques to improve sleep quality to women experiencing hot flashes is also
appropriate.
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Appendix A: Hot Flash Diary

1. How many hot flashes have you had in the past 24 HOURS? _____
2. How many of those were while you were sleeping? _____
3. Using the attached sheet as a guide, tell me how many of the hot flashes you have
had in the past 24 HOURS were mild, moderate, severe, or very severe.
_____ mild
_____ moderate
_____ severe
_____ very severe
4. How bothered are you by your hot flashes on a scale from 0 to 10 (0 is not bothered
at all, 10 is extremely bothered)? ____
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Appendix B: Hot Flash Severity Definitions
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Appendix C: Hot Flash Related Daily Interference Scale
Please circle one number to the right of each phrase to describe how much DURING THE PAST
WEEK, hot flashes has INTERFERED with each aspect of your life.

1. Work (work
outside the home
and housework)

Does not
Interfere
0
1

2

3

4

5

6

7

Completely
interferes
8
9
10

2. Social activities
(time spent with
family, friends, etc)

0

1

2

3

4

5

6

7

8

9

10

3. Leisure activities
(time spent
relaxing, doing
hobbies, etc.)

0

1

2

3

4

5

6

7

8

9

10

4. Sleep

0

1

2

3

4

5

6

7

8

9

10

5. Mood

0

1

2

3

4

5

6

7

8

9

10

6. Concentration

0

1

2

3

4

5

6

7

8

9

10

7. Relations with
others

0

1

2

3

4

5

6

7

8

9

10

8. Sexuality

0

1

2

3

4

5

6

7

8

9

10

9. Enjoyment of life

0

1

2

3

4

5

6

7

8

9

10

10. Overall quality of
life

0

1

2

3

4

5

6

7

8

9

10
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Appendix D: Pittsburgh Sleep Quality Index
The following questions relate to your usual sleep habits DURING THE PAST SIX WEEKS.
Your answers should reflect the majority of days and nights during the past six weeks.
1. During the PAST SIX WEEKS, when have you usually gone to bed at night?
______ Usual bed time
2. During the PAST SIX WEEKS, how long has it usually taken you to fall asleep at night?
______ Number of minutes
3. During the PAST SIX WEEKS, when have you usually gotten up in the morning?
______ Usual getting up time
4. During the PAST SIX WEEKS, how many hours of actual sleep did you get at night?
(This may be different than the number of hours you spent in bed.)
______ Hours of sleep per night
For each of the remaining questions, check the one best response. Please answer all questions.
During the PAST SIX WEEKS, how often have you had trouble sleeping because you…
Not
during
the past
month
0

Less than
once a
week

Once or
twice a
week

Three or
more times
a week

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

10. Feel too cold

0

1

2

3

11. Feel too hot

0

1

2

3

12. Had bad dreams

0

1

2

3

13. Have pain

0

1

2

3

14. Other reasons

0

1

2

3

5. Cannot get to sleep
within 30 minutes
6. Wake up in the middle of
the night or early
morning
7. Have to get up to use the
bathroom
8. Cannot breathe
comfortably
9. Cough or snore loudly
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Appendix D: Pittsburgh Sleep Quality Index
15. During the PAST SIX WEEKS how would you rate your sleep quality overall?
(CHECK ONE)
______ Very good
______ Fairly good
______ Fairly bad
______ Very bad

16. During the PAST SIX WEEKS, how often have you taken medicine (prescribed or “over
the counter”) to help you sleep? (CHECK ONE)
______ Not during the past month
______ Less than once a week
______ Once or twice a week
______Three or more times a week
17. During the PAST SIX WEEKS, how often have you had trouble staying awake while
driving, eating meals, or engaging in social activities? (CHECK ONE)
______ Not during the past month
______ Less than once a week
______ Once or twice a week
______Three or more times a week
18. During the PAST SIX WEEKS, how much of a problem has it been for you to keep up
enough enthusiasm to get things done? (CHECK ONE)
______ No problem at all
______ Only a very slight problem
______ Somewhat of a problem
______ A very big problem
19. Do you have a bed partner or roommate? (CHECK ONE)
______ No bed partner or roommate
______ Partner/roommate in other room
______ Partner/roommate in same room, but not in same bed
______ Partner in same bed
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Appendix E: Demographic Questionnaire
DEMOGRAPHIC QUESTIONNAIRE

What is your age? ______ (on your last birthday)

What is your ethnicity?
White
African-American
Hispanic
American Indian
Asian
Pacific Islander

Please circle the highest grade of education you
completed.
1
2
3
4
5
6
7

_____ (1)
_____ (2)
_____ (3)
_____ (4)
_____ (5)
_____ (6)

8

9

10

11

12 (high school)

13

14

15

16 (college)

17

18 (master’s degree)

19

20 (doctorate)

What medications or supplements are you currently taking? (Please list all vitamins, herbs,
supplements, and medications, including pills, inhalers, injections, and creams)
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
Do you have any chronic medical problems, such as arthritis or high blood pressure?
___ no (0)
___ yes (1), please list any medical problems:
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
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Appendix F: Disease and Treatment Information
DISEASE & TREATMENT INFORMATION (To be filled out by researcher)

DIAGNOSIS
Date: ____-____-____

SURGERY
Date: ____-____-____

Location: ___ left (1)___ right (2)___ bilateral (3)

Type:
_____ lumpectomy (1)
_____ MRM (2)
_____ RM (3)
_____ other (4)

Stage: T ___ N ___ M ___
X
0
I
IIA
IIB
IIIA
IIIB
IV

_____ (0) (any Tx, any Nx, any Mx)
_____ (1)
_____ (2)
_____ (3)
_____ (4)
_____ (5)
_____ (6)
_____ (7)

Hysterectomy:
___ yes, with oopherectomy (1)
___ yes, without oopherectomy (2)
___ no (3)

CHEMOTHERAPY
_____ none (0)
_____ some (1), # cycles received? _____

RADIATION THERAPY
_____ none (0)
_____ some (1)

Begin date:
End date:

Begin date:
End date:

____-____-____
____-____-____

ANTI-ESTROGEN THERAPY (current use)
___ no (0)
___ tamoxifen (Nolvadex)(1)
___ toremifene (Fareston) (2)
___ raloxifene (Evista) (3)
Begin date: ____-____-____
End date: ____-____-____

____-____-____
____-____-____

Complete Treatment Received:
_____ surgery alone (1)
_____ surgery + XRT (2)
_____ surgery + chemo (3)
_____ surgery + XRT + chemo (4)
Date of last treatment:
____-____-____
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